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Abstract Replication-dependent (RD) core histone mRNA produced during S-phase is the only
known metazoan protein-coding mRNA presenting a 3’ stem-loop instead of the otherwise
universal polyA tail. A metallo b-lactamase (MBL) fold enzyme, cleavage and polyadenylation
specificity factor 73 (CPSF73), is proposed to be the sole endonuclease responsible for 3’ end
processing of both mRNA classes. We report cellular, genetic, biochemical, substrate selectivity,
and crystallographic studies providing evidence that an additional endoribonuclease, MBL domain
containing protein 1 (MBLAC1), is selective for 3’ processing of RD histone pre-mRNA during the
S-phase of the cell cycle. Depletion of MBLAC1 in cells significantly affects cell cycle progression
thus identifying MBLAC1 as a new type of S-phase-specific cancer target.
DOI: https://doi.org/10.7554/eLife.39865.001
Introduction
During S-phase of the cell cycle, production of the core histone proteins (H2A, H2B, H3, and H4) is
coordinated with DNA replication (Harris et al., 1991; Ewen, 2000). Metazoan mRNAs encoding
for the ‘replication-dependent’ (RD) core histones lack the normal polyA tail formed by 3’ end hydro-
lysis of pre-mRNA followed by polyadenylation (Proudfoot, 2011). Instead, they undergo endonu-
cleolytic cleavage at the 3’ side of an RNA hairpin (stem loop) producing mRNA with a 3´stem loop
(SL), which is exported from the nucleus for use in translation (Marzluff et al., 2008; Marzluff and
Koreski, 2017). By contrast, the pre-mRNA of replication-independent histone variants are normally
polyadenylated and constitutively expressed during the cell cycle (Marzluff et al., 2002;
Wagner et al., 2007).
A single endonuclease, cleavage and polyadenylation specificity factor 73 (CPSF73), is proposed
to be responsible for the hydrolysis of both RD histone pre-mRNA (SL) and normal protein-coding
pre-mRNA (polyA) (Dominski et al., 2005; Mandel et al., 2006; Kolev et al., 2008; Sullivan et al.,
2009b; Dominski, 2010). Although maturation of both classes of RNAs requires a hydrolytic reac-
tion, different macromolecular complexes are recruited to the different pre-mRNA classes (SL or
polyA) (Kolev et al., 2008; Sullivan et al., 2009b). Specific factors involved in RD histone pre-mRNA
maturation are the stem loop binding protein (SLBP), the FLICE-associated huge protein (FLASH),
and the U7 small nuclear ribonucleoprotein (U7snRNP) that binds to a histone downstream element
(HDE) (Dominski et al., 2005; Kolev et al., 2008; Sullivan et al., 2009b). Defective 3’ end process-
ing of RD histone pre-mRNA, caused by depletion of factors including CPSF73, SLBP, Sm-like pro-
tein 11 (Lsm11), CstF64 or FLASH, results in the generation of extended transcripts downstream of
the HDE sequence (Sullivan et al., 2009a; Romeo et al., 2014; Sullivan et al., 2009b). In Drosophila
melanogaster and humans, misprocessed RD histone pre-mRNA has been observed to undergo pol-
yadenylation involving utilization of a secondary polyadenylation signal sequence located
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downstream of the HDE (Sullivan et al., 2009b; Romeo et al., 2014; Kari et al., 2013). Depletion
of factors belonging to the 5’ cap-binding complex (CBC) (Hallais et al., 2013, Narita et al., 2007;
Gruber et al., 2012), or to the cleavage factor II (CF IIm), which is normally involved in 3’ end proc-
essing of normal protein-coding pre-mRNA (polyA) (Hallais et al., 2013; de Vries et al., 2000), also
results in extended RD histone pre-mRNA transcripts (Hallais et al., 2013). These observations sug-
gest a complex and dynamic relationship between the factors involved in the different stages of the
RD histone pre-mRNA transcription process, which may involve participation of factors normally
belonging to the polyA mRNA processing machinery.
Important cancer medicines, including histone deacetylase and cyclin-dependent kinase inhibi-
tors, target proteins involved in the S-phase (Newbold et al., 2016; Falkenberg and Johnstone,
2014). In work aimed at identifying potential new S-phase cancer targets, we considered known and
potential roles of MBL-fold proteins involved in nucleic acid hydrolysis (Dominski, 2007;
Pettinati et al., 2016; Daiyasu et al., 2001). In addition, to the role of CPSF73, and the likely
pseudo-enzyme CPSF100, in pre-mRNA processing (Dominski et al., 2005; Mandel et al., 2006),
MBL-fold nucleases are involved in DNA repair (SNM1A-C nucleases) (Yan et al., 2010), snRNA
processing (INTS9 and INTS11), and tRNA processing (ELAC 1 and 2) (Skaar et al., 2015;
Vogel et al., 2005). Whilst most of the ~18 human MBL-fold proteins have established functions
(Pettinati et al., 2016), the functions of several are unassigned, including the MBL domain contain-
ing protein 1 (MBLAC1). Here, we report evidence that MBLAC1 is a nuclease specific for cleavage
of RD histone pre-mRNA. Crystallographic and biochemical studies show that MBLAC1 has an over-
all MBL fold and di-zinc ion containing active site related to that of CPSF73, but which has distinctive
structural features involving active site flanking loops and the absence of the b-CASP domain, which
is only present in CPSF73. MBLAC1 depletion from cells leads to the production of unprocessed RD
histone pre-mRNA due to inefficient 3’ end processing. The consequent depletion of core histone
proteins correlates with a cell cycle defect due to a delay in entering/progressing through S-phase.
Results
MBLAC1 structure reveals similarity with MBL-fold nucleases
On the basis of sequence similarity studies MBLAC1 has been assigned as an RNAse Z and glyoxa-
lase II subfamily enzyme (Ridderstro¨m et al., 1996; Sievers et al., 2011) (Figure 1—figure supple-
ment 1A). However, we found that recombinant MBLAC1 prepared from E. coli has only low, likely
non-specific, glyoxalase activity as observed for other hMBL-fold proteins belonging to the same
subfamily (Shen et al., 2011). To investigate its function, we solved a crystal structure of MBLAC1
(1.8 A˚ resolution, space group P1) (Table 1). The structure reveals a stereotypical abba MBL- fold
(Carfi et al., 1995) with two central mixed b-sheets (I and II), comprised of 8 and 5 strands respec-
tively, surrounded by helices (Figure 1A). In b-sheet I, b-strands 1, 2, 5–6 and 8–10 are anti-parallel,
with b-strands 6–8 being parallel; b-strands 3 and 4 are part of a loop region and are aligned anti-
parallel to each other and parallel to b-strands 2 and 5, respectively. In b-sheet II, b-strands 11, 12,
13 and 14 are anti-parallel, and b-strands 14 and 15 are parallel (Figure 1A). MBLAC1 has four of
the five characteristic MBL-metal-binding motifs (Pettinati et al., 2016), His116, His118 Asp120 and
His121 (motif II), His196 (motif III), Asp221 (motif IV) and His263 (motif V) (Figure 1B) (using BBL
numbering) (Galleni et al., 2001) with two waters completing metal coordination. In the structure of
recombinant MBLAC1 produced in E. coli, the active site was refined with two iron ions present
(Figure 1B). However, MBLAC1 produced in HEK293 cells preferentially binds zinc ions (Figure 1C).
Four MBLAC1 molecules (chains A-D) are present in the crystallographic asymmetric unit; analysis of
interactions at the crystallographically observed monomer interfaces (Krissinel and Henrick, 2007)
identified interactions between chains A-B and C-D (Figure 1D) possibly reflecting dimeric MBLAC1
in solution (Figure 1E and F). The metal containing active site is adjacent to the dimer interface
(Figure 1D), rationalizing reduced dimerization as manifested by metal ligand substitution or metal
removal (Figure 1E–G).
Comparison of the MBLAC1 structure with those of other MBL-fold proteins reveals that it is
indeed part of the RNAse Z/glyoxalase II MBL structural subfamily (Figure 1H; Figure 1—figure sup-
plement 1B–C). However, although there is low overall sequence similarity (27%), the overall
MBLAC1 fold is structurally similar to the human endoribonuclease b-lactamase-like-protein 2
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(Levy et al., 2016) (LACTB2), RMSD 2.23 A˚ over 153 Ca atoms (Laskowski et al., 2005)
(Figure 1H), an endoribonuclease responsible for mitochondrial mRNA maturation (Levy et al.,
2016). Comparison of the MBLAC1 and LACTB2 active sites reveals very similar di-metal ion binding
modes and proximate active site residues (Figure 1—figure supplement 1B). Two loops close to
the MBLAC1 active site (b3-b4 and b14-a3 loops) are also present in LACTB2 (b1-b2 and b11-a3
loop) (Figure 1H), suggesting the enzymes have similar substrate recognition/catalytic mechanisms.
Studies on the ‘true’ MBLs involved in b-lactam antibiotic resistance, imply the two active site loops
of MBLAC1 are likely mobile and involved in induced fit binding and in substrate recognition
(Brem et al., 2015), thus it is possible that the crystallographically observed loop conformations
reflect those involved in productive substrate binding/catalysis. Two other regions in the MBLAC1
structure (aa 51–66 and the C-terminal region, aa 239–266) are disordered, implying flexibility and
possible involvement in substrate recognition. LACTB2 is reported to have high overall structural
similarity with CPSF73 (Levy et al., 2016). However, whilst comparison of the MBL domains of
Table 1. Crystallographic data and refinement statistics PDB ID 4V0H.
Native HSE
(PDB ID: 4V0H)
Data collection
Space group P1
Cell dimensions
a, b, c (A˚) 62.95, 67.13, 67.90
a, b, g (˚) 109.31, 105.40, 90.17
Resolution (A˚) 45.96–1.79 (1.84–1.79 A˚)*
Rmerge
† 0.10 (0.81)
I/s(I) 12.4 (2.6)
Completeness (%) 95.5 (92.6)
Redundancy 6.9 (6.7)
Refinement
Resolution (A˚) 45.95–1.79
No. reflections 90641
Rwork
‡/Rfree
§ 0.182/0.211
No. atoms
Protein 6235
Ligand/ion 38
Water 514
B factors
Protein 27.27
Ligand/ion 44.40
Water 33.94
R.m.s. deviations
Bond lengths (A˚) 0.01
Bond angles (˚) 1.37
* Values in parentheses are for highest-resolution shell.
†Rmerge =
P
h
P
l | Ihl - < Ih > | /
P
h
P
l < Ih > where Ihl is the lth observation of reflection h, and <Ih > is the mean
intensity of that reflection.
‡Rwork =
P
|| Fobs |-|Fcalc||/|Fobs| x 100.
§Rfree is calculated in the same way as Rwork but using a test set containing 5.01% of the data, which were excluded
from the refinement calculation.
DOI: https://doi.org/10.7554/eLife.39865.004
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Figure 1. MBLAC1 is a dimeric metallo b-lactamase fold protein related in structure to LACTB2. (A) View from an MBLAC1 crystal structure (PDB ID:
4V0H) showing secondary structure elements and the di-metal containing active site. Helices are in cyan, b-strands in yellow, and metal ions are orange
spheres. Dashed line (in gray) indicates unrefined residues (aa 51–66). (B) View of metal binding and active site residues with a representative electron
density map (3.0 s mFo-DFc OMIT; cyan mesh) for the sidechains of His116 (Ne2 to M1: 2.33 A˚), His118 (Ne1 to M1: 2.35 A˚), Asp120 (Od2 to M2: 2.9 A˚),
Figure 1 continued on next page
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MBLAC1 and CPSF73 reveals similar di-zinc ion binding modes, there are clear differences in their
active site flanking loops; only the b3-b4 MBLAC1 active site loop (b1-b2 in LACTB2), is present in
CPSF73 (b1-b2 loop), where it is relatively shorter (Figure 1—figure supplement 1D).
Loss of MBLAC1 impairs cell cycle progression
We sought to gain insight into the biological role of MBLAC1 by its depletion in HeLa cells using
siRNA. Flow cytometry reveals that unsynchronised cells depleted for MBLAC1 show a cell cycle
defect (Figure 2A). This is manifested by increased accumulation of cells in G1/early S-phase and
decreased proportions of cells in G2 compared to controls. Furthermore, cells synchronised in early
S-phase using a double thymidine block (Harper, 2005) and harvested immediately after block
release show the expected G1/early S phenotype (Figure 2A). However, 4 hours post-release, con-
trol cells progressed normally through the cell cycle, while MBLAC1 depleted cells displayed a
strong delay in G1/early S-phase. Western blots were then used to investigate the nature of the
delay in cell cycle progression by monitoring levels of cyclin D1, a cell cycle protein marker
expressed during G1 (Darzynkiewicz et al., 1996) (Figure 2B). Cyclin D1 was hardly detectable in
controls, but was strongly upregulated with MBLAC1 depletion (Figure 2B). These results are consis-
tent with a relatively stronger G1 block with MBLAC1 depletion compared to control cells
(Figure 2A–B). Given a possible role for MBLAC1 in cell cycle progression, both unsynchronised and
early S-phase synchronised wild-type HeLa cells (using a double thymidine block) were used to inves-
tigate the endogenous subcellular distribution of MBLAC1 during S-phase. Western blot analyses
reveal the presence of MBLAC1 in both the cytosol and nucleus (Figure 2C). However, a fraction of
MBLAC1 was consistently observed to localise in the nuclear compartment during early S-phase of
the cell cycle (and less consistently at later S-phase time points), suggesting a cell-cycle-dependent
nuclear function for MBLAC1.
Following the observation of nuclear localised MBLAC1 during S-phase and our crystallographic
analyses which suggested MBLAC1 as a possible ribonuclease distinct from, but related to, CPSF73,
both proteins were depleted in HeLa cells using siRNA to investigate the roles of MBLAC1 in
S-phase. Incorporation of 5-bromo-2’-deoxyuridine (BrdU) into newly synthesised DNA in synchron-
ised cells was monitored by flow cytometry (Figure 3A, left graph) followed by propidium iodide (PI)
staining (Figure 3—figure supplement 1). The abundance of BrdU positive cells, corresponding to
S-phase cells, was strongly reduced in MBLAC1 and CPSF73 knockdowns at early time points (30
min, 1 hr), compared to controls (Figure 3A, left graph). Subsequent time points displayed a
reduced difference, though 6 hr post release a consistent pool of G1 cells was still apparent in
Figure 1 continued
His121 (Ne2 to M2: 2.37 A˚), His196 (Ne2 to M1: 2.27 A˚), Asp221 (Od2 to M1: 2.14 A˚; Od2 to M2: 2.12 A˚), His263 (Ne2 to M2: 2.06 A˚) and the two water
molecules (red spheres) which coordinate (black dashed lines) to the metals (orange spheres). The BBL MBL numbering system is used (Galleni et al.,
2001) (active site motif numbers in parentheses) (Pettinati et al., 2016). Numbering as used in our PDB deposited structure is in bold. (C) Inductively
coupled plasma mass spectrometry (ICP-MS) experiments reveal that in human cells MBLAC1 binds zinc. (D) MBLAC1 dimer model calculated by PISA
(Krissinel and Henrick, 2007). A surface representation is shown for protomer A/C. (E) Multi-angle laser light scattering (MALS) analyses of E. coli
produced wt and active site variant MBLAC1, and of HEK293 produced wtMBLAC1. Peak A likely represents a trimer (~80000 Da); peak B (~54000 Da) a
dimer; and peak C (~27000 Da) a monomer. wt MBLAC1 is predominantly dimeric, the active site variant is mainly monomeric. The latter observation
correlates with loss of activity of active site variant MBLAC1 (main text Figure 4a), the proposal that the dimer is catalytically active, and the observation
that the active site is close to the dimer interface. MALS experiments were carried out at the Biophysical Services of the Biochemistry Dept., Oxford
University. (F) Non-denaturing PAGE analyses indicates wt MBLAC1 produced in either E. coli or HEK293 cells is predominantly dimeric; a higher
oligomeric state (tetramer) is also observed for the bacterial produced wt protein. The active site substituted enzyme produced in E. coli shows loss of
oligomerization. wtMBLAC1 produced in either, E. coli or HEK293 cells shows the same oligomerization behavior. (G) Non-denaturing electrospray
ionization mass spectrometry deconvoluted spectra of recombinant MBLAC1 produced in E. coli indicates that MBLAC1 is dimeric, binding two metal
ions. Peak A (54880 Da) represents the dimer with two divalent transition metal ions (zinc or iron) bound to each monomer (+224 Da); peaks B and C
(27440 and 54880 Da, respectively) correspond to monomer and dimer without bound metal, following metal removal using EDTA. (H) Superimposition
of the MBLAC1 (cyan; metals in orange) and LACTB2 folds (PDB ID: 4AD9) (Levy et al., 2016) (pink; metals in grey) reveals a high degree of overall
similarity (RMSD 2.2 A˚ over 153 Ca atoms).
DOI: https://doi.org/10.7554/eLife.39865.002
The following figure supplement is available for figure 1:
Figure supplement 1. Structural comparison of MBLAC1 with ribonucleases from the MBL superfamily and with glyoxalase II.
DOI: https://doi.org/10.7554/eLife.39865.003
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MBLAC1-depleted cells compared to both control and CPSF73-depleted cells (Figure 3—figure
supplement 1). These results indicate that both MBLAC1 and, as expected, CPSF73 depleted cells
are impaired in efficiently entering/progressing in S-phase. Although both depletions displayed a
delay 30 min post-release, the defect was more pronounced with MBLAC1 depletion over the full
cell cycle, implying a cell-cycle-specific role for MBLAC1 (Figure 3—figure supplement 1). Western
blot analyses indicated that in control samples (siLuc) MBLAC1 levels were increased 6 hr post-
release (Figure 3B) corresponding to mid S-phase (as shown by flow cytometry profiles, Figure 3—
figure supplement 1). These observations support a specific role for MBLAC1 during S-phase. By
contrast, CPSF73 expression levels were relatively constant across the cell cycle (18 hr), consistent
with its broad role in pre-mRNA processing (Mandel et al., 2006) (Figure 3B). Although both
MBLAC1 and CPSF73-depleted cells progress through the complete cell cycle, levels of cyclins D1
(G1 marker) and E (a G1/S boundary and S progression marker) were strongly modified compared to
controls. As described above, cyclin D1 levels were strongly upregulated with MBLAC1 depletion,
while cyclin E levels were reduced compared to controls. Notably for CPSF73 depletion, cyclins D1
and E showed intermediate levels compared to MBLAC1 depletion and controls (Figure 3B). Given
the strong correlation between S-phase and histone biosynthesis (Harris et al., 1991; Ewen, 2000),
histone H3 levels were used to analyse RD histone protein abundance in MBLAC1 and CPSF73
depleted cells. Notably, H3 levels were reduced in MBLAC1 depleted cells; by contrast, CPSF73
Figure 2. Loss of MBLAC1 impairs cell cycle progression. (A) Cell cycle analyses of MBLAC1-depleted cells. Analyses were on unsynchronised cells, or
after cell synchronization (using a double thymidine block) as indicated. Flow cytometry profiles were obtained by PI staining. Control siRNA (siLUC)
transfected cells were used for reference. (B) Western blots evaluating knockdown efficiency of MBLAC1 after siRNA treatment, in unsynchronised and
synchronised cells. Cyclin D1 (G1 marker) levels were analysed. b-Actin was used as a control. Control siRNA (siLUC) transfected cells were used for
reference. (C) Western blot analysis showing cellular distribution of endogenous MBLAC1 after subcellular fractionation in unsynchronised (-) and early
S-phase synchronised HeLa cells (+) at different time points after release from a double thymidine block. Note the presence of MBLAC1 in the nucleus
in early S-phase. a-Tubulin and lamin A/C were used as cytosolic and nuclear markers, respectively.
DOI: https://doi.org/10.7554/eLife.39865.005
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Figure 3. Loss of MBLAC1 impairs normal entrance to S-phase and S-phase progression. (A) Comparative quantification of BrdU-positive cells
corresponding to early-S cells in MBLAC1 and CPSF73-depleted cells and MBLAC1 CRISPR KD (CRISPR/Cas9 mediated KD) cells after synchronization.
Control siRNA (siLUC) transfected cells and wt HeLa cells were used for comparison. Error bars represent SEM from three independent biological
replicates. Asterisks indicate the statistical significance using the two way ANOVA tool followed by the Bonferroni multiple comparison tool in
Graphpad Prism five software: *, p<0.05; **, p<0.001; ***, p<0.0001. Unlabeled variations were considered not statistically relevant. (B) Western blot
analyses evaluating MBLAC1 and CPSF73 knockdown efficiency and effects on cyclin D1, cyclin E and histone H3 levels. (C) Cell cycle analysis of
MBLAC1 CRISPR/Cas9 mediated stable knockdown (CRISPR KD) cells after synchronization in early S-phase. Flow cytometry profiles obtained by
double-staining with an anti-BrdU antibody (upper panels) and PI (lower panels). wt HeLa cells were used for reference. Abbreviations: ES, early
S-phase; LS, late S-phase. (D) Western blot analyses evaluating MBLAC1 CRISPR/Cas9-mediated stable knockdown efficiency and effects on cyclin D1, E
and histone H3 levels (with synchronised cells treated with BrdU, 30-min incubation).
DOI: https://doi.org/10.7554/eLife.39865.006
The following figure supplements are available for figure 3:
Figure supplement 1. Loss of MBLAC1 impairs normal entering of S-phase and S-phase progression.
DOI: https://doi.org/10.7554/eLife.39865.007
Figure supplement 2. MBLAC1 CRISPR/Cas9 stable knockdown and FLAG knock in validation, wild-type-like cell phenotype restoration and MBLAC1
interactors.
DOI: https://doi.org/10.7554/eLife.39865.008
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depletion showed an intermediate H3 level compared to controls (Figure 3B). A more severe pheno-
type was observed in an MBLAC1 stable knockdown (Figure 3A right graph, C, D) (Figure 3—fig-
ure supplement 2A–C) generated in HeLa cells by CRISPR/Cas9 gene editing. This observation
supports a specific role for MBLAC1 in cell cycle regulation, in particular on entering/progressing
through S-phase (Figure 3A right graph, C). As for the siRNA-mediated knockdown experiments,
CRISPR/Cas9 depletion of MBLAC1 results in an altered production of cyclin E and reduced level of
H3. By contrast, cyclin D1 levels appear unchanged, possibly due to a mechanism of cellular adapta-
tion under unfavourable conditions (Figure 3D).
Treatment of MBLAC1 CRISPR/Cas9-mediated knockdown (CRISPR KD) cells with isolated recom-
binant MBLAC1 partially restored the wild-type cell phenotype leading to dose-dependent increas-
ing levels of cyclin E and histone H3 compared to untreated MBLAC1 KD cells after synchronization
in early S-phase (Figure 3—figure supplement 2D). These observations support a direct role for
MBLAC1 during S-phase of the cell cycle. The subcellular distribution of ectopically administered
recombinant MBLAC1 in CRISPR/Cas9-mediated knockdown cells appears to be very similar com-
pared to that of wild-type HeLa cells (Figure 3—figure supplement 2E), indicating that application
of recombinant MBLAC1 partially restores the wild-type like phenotype by localizing to the correct
cellular compartment during S-phase.
MBLAC1 is involved in histone-specific pre-mRNA processing in vivo
Given the established role of CPSF73 as a nuclear ribonuclease responsible for pre-mRNA 3’ end
maturation (Dominski et al., 2005; Mandel et al., 2006), we investigated such a role for MBLAC1.
MBLAC1 was depleted in HeLa cells using siRNA as, for comparison, was CPSF73 (Figure 4A). To
evaluate not only the polyadenylated mRNA population (polyA), but also RD histone mRNA (SL)
processing, cells were synchronised in early S-phase and chromatin associated RNA was extracted to
capture nascent transcripts (Nojima et al., 2015). Chromatin RNA-seq (ChrRNA-seq) analyses for a
typical polyA mRNA encoding gene, for example glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), displayed clear transcription termination defects downstream of the transcription end site
(TES) in CPSF73, but not MBLAC1, depleted cells, nor in a siRNA controls (Figure 4B; Figure 4—fig-
ure supplement 1A). Unexpectedly, RD histone genes (SL) showed apparent transcription termina-
tion defects, not only in CPSF73, but also in MBLAC1, depletions (Figure 4C; Figure 4—figure
supplement 1B). Importantly, 43 non-overlapping RD histone genes were analysed; of these 29 RD
histone genes manifested clear transcription termination defects, in both the MBLAC1 and CPSF73-
depleted samples (evidence for/exceptions are HIST1H2AI and HIST4H4 genes on which CPSF73
depletion apparently does not show an effect); a possible effect was observed on 7 RD histone
genes (Figure 4—figure supplements 2,3), and no apparent effect was detected on seven remain-
ing RD histone genes (Figure 4—figure supplements 2,4). Where observed, read through (RT) tran-
scripts corresponding to this defect were detectable covering ~200 bases downstream of the
transcription end site (TES) with the RD histone genes (Figure 4—figure supplements 2,3). The
comparison of the read through of MBLAC1 to that of CPSF73 depletion shows a similar transcrip-
tion termination defect pattern affecting similar genes with a few exceptions (Figure 4—figure sup-
plements 2,4); it is possible that both MBLAC1 and CPSF73 may affect overlapping sets of histone
genes, but to different extents.
Quantitative reverse transcription PCR (RT-qPCR) analyses validated the transcriptomics results.
With normal protein-coding mRNA (GAPDH), transcription termination was substantially affected by
CPSF73, but not MBLAC1, depletion (Figure 4D). The abundance of termination defective (3’ end
extended) RD histone mRNA increased in both MBLAC1- and CPSF73-depleted cells compared to
controls (Figure 4D) supporting the proposal that MBLAC1 is a RD histone selective pre-mRNA
processing enzyme. Consistent with this proposal, the relative levels of defective transcripts quanti-
fied by RT-qPCR analyses reflected the difference observed during ChrRNA-seq analyses between
different replication-dependent histone genes (e.g. a stronger defect was observed on HIST1H2BC,
compared to HIST4H4, mRNA) (Figure 4C,E; Figure 4—figure supplement 2B).
Single gene analyses on chrRNA confirmed the increased abundance of termination defective (3’
end extended) RD histone mRNA in MBLAC1 CRISPR/Cas9-mediated knockdown cells compared to
wildtype HeLa cells, after synchronization in early S-phase (Figure 4E). This result supports the
observed altered cell cycle phenotype as observed following depletion of MBLAC1 using siRNA (Fig-
ures 2 and 3). To investigate the nature of these defective transcripts, total RNA extracted from
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Figure 4. Loss of MBLAC1 leads to 3’ end processing defects in replication dependent histone pre-mRNA. (A) Western blots showing the knockdown
efficiency of siRNA treatments for MBLAC1 and CPSF73 in synchronised HeLa cells (using b-actin as a control). (B, C) ChrRNA-seq analyses from one of
two biological replicates (Set2), on GAPDH or selected RD histone (HIST1H2BC) genes (UCSC Genome Browser) (Kent et al., 2002), following MBLAC1
or CPSF73 depletion. Arrows indicate gene bodies and transcription termination defect orientation. (D) Real-time qPCR quantification of 3’ end
Figure 4 continued on next page
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early S-phase synchronised HeLa cells (wildtype and the MBLAC1 CRISPR/Cas9-mediated knock-
down) was used to evaluate the accumulation of defective histone pre-mRNAs in either the polyade-
nylated (polyA+) or unpolyadenylated (polyA-) RNA cellular fractions (Figure 4—figure supplement
1C–E). Quantitative reverse transcription PCR (RT-qPCR) analyses showed a low (~15%), but consis-
tent, increase in polyA +histone transcripts in MBLAC1-depleted cells compared to wild-type cells
(Figure 4—figure supplement 1C). By contrast, in both wild-type and MBLAC1-depleted cells, the
polyA- fraction showed a similar, or reduced, abundance of histone transcripts. These observations
support previous studies (Sullivan et al., 2009b; Romeo et al., 2014; Kari et al., 2013), by implying
that RD histone pre-mRNA can undergo polyadenylation when inefficiently processed at their normal
3’ processing site.
To further investigate the involvement of MBLAC1 in RD histone pre-mRNA cleavage in vivo,
RNA-Chromatin immunoprecipitation (RNA-ChIP) experiments (Sun et al., 2006) (Figure 4F–G)
were carried out using a C-terminal FLAG tagged MBLAC1 knock in generated in HeLa cells by
CRISPR/Cas9 technology (Figure 3—figure supplement 2F, G). The results provided evidence that
MBLAC1 specifically associates with chromatin associated histone mRNA during early S-phase, but
that it either does not interact, or interacts to a lesser extent (similarly to FLASH) (Figure 4F–G), with
normal protein coding mRNA (GAPDH); a similar amount of FLASH was recruited on histone RNA
compared to MBLAC1. FLASH was used as control in our experiments as it is a well-established com-
ponent of the histone 30 end processing complex (Marzluff and Koreski, 2017) (Figure 4F). Note
that RD histone mRNA relative levels are not affected by the tagging of MBLAC1 as observed by
comparison of wild-type and MBLAC1 C-terminal FLAG knock HeLa cells RNA-ChIP input samples
(Figure 4G).
MBLAC1 shows endoribonucleolytic activity in vitro
The combined observations described above indicated that MBLAC1 is a ribonuclease, which is pos-
sibly involved in RD histone pre-mRNA processing. We therefore purified recombinant wild-type
MBLAC1 (wtMBLAC1) and a H196A/D221A/H263A variant (mutMBLAC1) (with disrupted zinc ion
binding) (Figure 5A–B) from E. coli, as well as wtMBLAC1 produced in HEK293 cells. These protein
preparations were tested for ribonuclease activity using an internally a 32P UTP labeled RNA
Figure 4 continued
transcription termination defect following MBLAC1 and CPSF73 depletion on genes as in (b, c). Relative abundance (RA) of unprocessed RNA was
normalised to the abundance of GAPDH mRNA (black), or to that of the corresponding histone gene body (white) (Table 2). Error bars represent SEM
from four biological replicates. Asterisks indicate the statistical significance observed using the two-tailed t-test (**p<0.01). Abbreviations: GB, gene
body; RT, read through; TES, transcription end site. (E) Real Time-qPCR quantification of 3’ end transcription termination defect in the MBLAC1
CRISPR/Cas9-mediated stable knockdown (KD) compared to wt HeLa cells. The relative abundance (RA) of unprocessed RNA was normalised to
GAPDH mRNA (black), or to the corresponding histone gene body abundance (white) (Table 2). Error bars represent SEM from four biological
replicates. Asterisks indicate the statistical significance observed using the two-tailed t-test (*,p<0.05, **, p<0.01, ***, p<0.001). Unlabeled variations
were considered likely not statistically relevant. (F) RNA-Chromatin immunoprecipitation (RNA-ChIP) analyses investigating the recruitment of MBLAC1
on histone RNA. RNA-ChIP signals are shown for MBLAC1 and FLASH in the MBLAC1 C-terminal FLAG knock in HeLa cells; the FLAG background
signal is shown in wild-type cells used as control for comparison. Note that both MBLAC1 and FLASH signals are comparable on normal protein coding
RNA (GAPDH). Error bars represent SEM from three (MBLAC1) or two (FLASH) biological replicates. (G) RNA-ChIP input samples relative comparison.
Histone mRNA relative abundance (in both wild-type and MBLAC1 C-terminal FLAG knock HeLa cells) was normalised to the abundance of GAPDH
mRNA in the corresponding sample. The observed results imply that the RD histone mRNA levels are not affected (within detection limits) by the
tagging of MBLAC1. Error bars represent SEM from three biological replicates.
DOI: https://doi.org/10.7554/eLife.39865.009
The following figure supplements are available for figure 4:
Figure supplement 1. 3’ end processing defects observed in replication-dependent histone pre-mRNA after MBLAC1 depletion and investigation of
the effect of MBLAC1 depletion on the polyadenylated fraction of histone mRNA in HeLa cells.
DOI: https://doi.org/10.7554/eLife.39865.010
Figure supplement 2. MBLAC1 and CPSF73 depletions affect RD histone pre-mRNA processing in vivo.
DOI: https://doi.org/10.7554/eLife.39865.011
Figure supplement 3. MBLAC1 and CPSF73 depletions affect RD histone pre-mRNA processing in vivo.
DOI: https://doi.org/10.7554/eLife.39865.012
Figure supplement 4. MBLAC1 and CPSF73 depletions affect RD histone pre-mRNA processing in vivo.
DOI: https://doi.org/10.7554/eLife.39865.013
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Figure 5. MBLAC1 has sequence-specific endoribonucleolytic activity on RD histone pre-mRNA. (A) Silver staining analyses showing purity of MBLAC1
protein preparations produced from different sources. Note all proteins are highly purified except mutMBLAC1 produced in HEK293 which presents
some contaminants. (B) Schematic view of metal binding and active site residues and the two water molecules (red spheres) observed to coordinate
(black dashed lines) to the metals (grey spheres) at the MBLAC1 active site by crystallography (numbering as in Figure 1). Active site residues
Figure 5 continued on next page
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substrate corresponding to a 350 nt 3’ positioned fragment of the human HIST2H3C gene, including
its 3’ processing elements (Figure 5C–D). Recombinant wtMBLAC1 purified from E. coli bacteria dis-
played significant nonspecific ribonucleolytic activity, degrading the substrate in a time dependent
manner. By contrast, mutMBLAC1 manifested very little activity over time under the same assay con-
ditions. Notably, the endoribonucleolytic activity of wtMBLAC1 purified from HEK293 cells using the
same a 32P UTP-labeled histone RNA fragment gave an apparently more specific cleavage pattern.
In particular, cleavage products corresponding in size to the biologically authentic 5’ and 3’ frag-
ments were manifested (Figure 5C) (shown by red arrows). This apparently more specific cleavage
by wtMBLAC1 when produced in HEK293 cells may reflect different kinetic properties, possibly
resulting from post-translational modifications, or more biologically correct metal complexation at
the active site (Figure 1C). Note that bacterial MBLfold hydrolases are active with Zn (II) and other
transition metals including Fe (II) (Cahill et al., 2016). To further exclude the possibility of contami-
nating nuclease activity in our protein preparations and therefore validate MBLAC1 endoribonucleo-
lytic activity, the previously described RNA substrate was also incubated with wtMBLAC1 and the
H196A/D221A/H263A variant (mutMBLAC1) purified from HEK293 cells (Figure 5D). Consistent with
the previous results using bacterial produced enzymes, we observed little residual activity when the
substrate was incubated with mutMBLAC1 compared to wtMBLAC1. We again observed a more
specific cleavage pattern with wtMBLAC1 from HEK293 cells rather than with the bacterial produced
wtMBLAC1 (Figure 5D).
We next investigated the potential cleavage specificity of MBLAC1 using a shorter a 32P UTP
internally labeled RNA substrate (WT RNA) and a variant with a single-nucleotide substitution (A/G)
at the major physiological histone pre-mRNA processing site (MUT RNA) (Figure 5E) (Furger et al.,
1998; Kolev and Steitz, 2005). Bacterially produced wtMBLAC1 showed clear ribonucleolytic activ-
ity with the WT RNA substrate in a time-dependent manner (Figure 5F). Major cleavage products
were observed (red arrow) at positions corresponding to the authentic 3’ processing position. How-
ever, little evidence for ribonucleolytic activity was observed when wtMBLAC1 was incubated with
MUT RNA (Figure 5F). This observation suggests that MBLAC1 specifically recognises the biologi-
cally authentic CA dinucleotide required for histone pre-mRNA maturation and that this site is critical
for recognition/initial cleavage/binding by MBLAC1. Mononucleotides were not observed to accu-
mulate under any of the tested conditions (data not shown) implying a lack of exonucleolytic activity
for MBLAC1. Thus, consistent with the crystallographically observed structural similarity between
MBLAC1 and LACTB2 (Levy et al., 2016) (Figure 1H), these results identify MBLAC1 as a ribonucle-
ase with endonucleolytic activity. Unlike purified CPSF73 (Mandel et al., 2006), which exhibits sub-
stantially sequence-independent ribonuclease activity, isolated MBLAC1 appears more sequence
selective especially with shorter RNA substrates (Figure 5F). These observations imply that, at least
in isolated form, MBLAC1 initially catalyses hydrolysis at the biologically validated CA cleavage site
with subsequent endonucleolytic cleavage occurring at other positions.
RNA elements required for MBLAC1 specific activity in vitro
Specific elements are required for maturation of histone pre-mRNA in vivo (Marzluff and Koreski,
2017); in particular, SLBP appears to be necessary for efficient processing through stabilization of
Figure 5 continued
substituted to alanine in the MBLAC1 variant (H196A/D221A/H263A) are in red. (C) Time-dependent in vitro cleavage assay using an internally labeled
[32P] histone 2H3C pre-mRNA fragment (350 nt) with E. coli produced wtMBLAC1, or an active site substituted MBLAC1 variant (H196A/D221A/H263A),
or HEK293 produced wtMBLAC1 (media secreted). Note only a fraction of the total RNA is hydrolyzed. (D) Time-dependent in vitro cleavage assay
using an internally labeled [32P] histone 2H3C pre-mRNA fragment (350 nt) with HEK293 produced wtMBLAC1, or an active site substituted MBLAC1
variant (H196A/D221A/H263A). The red arrows indicate the assigned position of 3’ end processing in vivo. Note that both wt and mutMBLAC1 used in
this experiment were purified from HEK293 cell lysates instead of from cell media due to the loss of secretion of the mutant enzyme in the cell media.
(E) Schematic view of the histone 2H3C pre-mRNA fragment (168 nt) used in the cleavage assays showing preferential cleavage occurs after the CA
dinucleotide located five nucleotides to the 3’ side of the stem loop. The single-nucleotide substitution (A/G) at the CA cleavage site is shown. (F) Time
dependence of E. coli produced wtMBLAC1 in vitro cleavage using an internally labeled [32P] unmodified (WT RNA), or with a single-nucleotide
substituted (MUT RNA) histone pre-mRNA fragment (as in E). The red arrows indicate the assigned position of 3’ end processing in vivo. Abbreviations:
HDE, histone downstream element; SL, stem loop.
DOI: https://doi.org/10.7554/eLife.39865.014
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the HDE-U7 snRNA interaction and the HLF complex involving symplekin, CPSF73, CPSF100, and
CstF64, which are required for the cleavage of the pre-mRNA (Dominski et al., 1999; Kolev et al.,
2008; Romeo et al., 2014). To investigate the specificity of the observed MBLAC1 hydrolytic activity
on histone pre-mRNA, 50 to 40 nucleotide RNA fragments corresponding to a portion of the RD
human histone HIST2H3C pre-mRNA were [g-32P] ATP 5’ labeled and incubated with wtMBLAC1
produced in HEK239 cells (50 ng) (Figure 6). The reaction catalysed by MBLAC1 on the wild-type
RNA 1 generated two main products assigned as 27 and 29 nucleotides long (based on our frag-
ment numbering system), corresponding to the ‘physiological’ major and minor cleavage sites
(Streit et al., 1993; Furger et al., 1998), respectively (Figure 6A). This observation is in agreement
with previous studies, where the major and minor cleavage sites were reported to occur 5 and 7
nucleotides after the stem-loop, respectively, that is ACCCA corresponding to cleavage in position
27, and ACCCACA corresponding to cleavage in position 29 (Scharl and Steitz, 1994;
Furger et al., 1998). When a single nucleotide in RNA 1 is mutated at position 27 (A/G), to abolish
the ‘physiological’ CA dinucleotide at this position (RNA 2), we observed production of a single
main processing product corresponding to cleavage at position 29 (Figure 6A). Although hydrolysis
of RNA 2 was clearly observed, it appeared less efficient compared to that of RNA 1. This observa-
tion is in agreement with the results described above where a single point mutation at position 27
negatively affects catalysis (Figure 5F). mutMBLAC1 purified from HEK293 cells was also tested
using RNA 2 to investigate its ability to hydrolase the substrates at specific positions; as anticipated,
mutMBLAC1 showed very little hydrolytic activity on RNA 2 compared to wtMBLAC1 (Figure 6B).
To further investigate the specificity of cleavage after the CA at position 27, the wild-type RNA was
modified to contain only one CA dinucleotide at position 27 (RNA 3). Incubation with MBLAC1 led
to the production of a single observed degradation product consistent with cleavage at position 27
(major cleavage site), but again with apparently impaired efficiency (Figure 6C). When the nucleo-
tide sequence of the stem-loop was inverted, to maintain secondary structure (RNA 4), the cleavage
reaction appeared less efficient, although the cleavage specificity was apparently not compromised
within our limits of detection (note that the processing products of RNA 4 has a slower electropho-
retic mobility) (Figure 6D). This observation suggests the precise stem-loop sequence composition
does not affect the correct positioning of MBLAC1 at the physiological CA cleavage site. When the
stem-loop sequence was modified to ablate its conformation (RNA 5), cleavage at position 27 (the
major cleavage site) was apparently completely abolished; instead, a major band was observed cor-
responding to cleavage at the CA, position 23, although longer degradation fragments were also
detected (consistent with cleavage at positions 29, and possibly 32, 35) (Figure 6E). The degrada-
tion patterns observed for RNA 4 and 5 imply that likely the stem-loop structure prevents MBLAC1
from accessing putative single-stranded cleavage sites located upstream of position 27, thus helping
to maintain specificity of cleavage at position 27. MBLAC1 activity was also evaluated on a fragment
lacking the HDE sequence (RNA 6); interestingly, with this substrate efficient cleavage was main-
tained and the major cleavage site (position 27) still recognised, although the cleavage specificity
was reduced, leading to the formation of additional degradation bands corresponding to hydrolysis
at all the CA dinucleotides present in the fragment 6 sequence (Figure 6F). Overall, these results
support the proposal that purified MBLAC1 displays significant histone mRNA 3’ end processing
specificity.
Discussion
The combined biochemical, cellular, and genetic analyses presented here provide clear evidence
that MBLAC1 is an endoribonuclease selective for 3’ end processing of RD histone pre-mRNA during
S-phase of the cell cycle. Assays with isolated recombinant MBLAC1 reveal it is selective for hydro-
lytic cleavage at the biologically relevant CA dinucleotides present 5 and 7 nucleotides downstream
of the stem-loop sequence in replication-dependent pre-mRNA (positions 27 and 29, respectively,
using our pre-mRNA numbering). Crystallographic and other biophysical analyses support the
assignment of MBLAC1 as a nuclease, which is related to CPSF73 in terms of the overall fold of its
MBL domain, but which has distinctive, structural features, possibly reflecting their different sub-
strate recognition and/or substrate binding modes (Figure 1 and Figure 1—figure supplement 1).
The results obtained by depletion of MBLAC1 using siRNA or CRISPR/Cas9 techniques support
the involvement of MBLAC1 in RD histone pre-mRNA processing in vivo. The slow growth rate of
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Figure 6. MBLAC1 shows specific endoribonucleolytic activity on histone pre-mRNA recognising specific sequence/structural RNA elements in vitro. (A,
C–F) Time-dependent in vitro cleavage assays using [g-32P] ATP 5’ labeled histone 2H3C RNA fragments (RNA 1–6) in the presence of HEK293
produced wtMBLAC1. (B) Time-dependent in vitro cleavage assays using [g-32P] ATP 5’ labeled histone 2H3C RNA 2 (50 nt) in the presence of HEK293
produced wild-type or mutMBLAC1. Cleavage products of RNA 2 after incubation with wtMBLAC1 (WT) are compared with those after incubation with
Figure 6 continued on next page
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MBLAC1-depleted cells (Figure 3—figure supplement 2) likely reflects its important role in RD his-
tone pre-mRNA processing which is required for normal progression through the cell cycle. The
observation of a cell cycle defect in entering/progressing through S-phase correlates with reduced
histone protein abundance in HeLa cells after depletion of MBLAC1, either using siRNA or CRISPR/
Cas9 (Figure 3). These results are in agreement with a defect in efficient histone pre-mRNA matura-
tion as we observed by chrRNA-seq analyses in HeLa cells depleted of MBLAC1 where RD histone
pre-mRNA transcripts manifested abnormally 3’ end extensions reflecting inefficient maturation. The
inability of MBLAC1-depleted cells to produce the appropriate amount of histone proteins due to
the lack of mature mRNA encoding for them is also consistent with occurrence of a ‘G1-like’ block,
as observed by flow-cytometry and western blot analyses (Figure 3 and Figure 3—figure supple-
ment 1). These results imply that during S-phase, MBLAC1 has a specialised role in RD histone pre-
mRNA processing.
Studies with recombinant MBLAC1 purified from human or E. coli cells, define MBLAC1 as an
endoribonuclease, with selectivity for cleavage at the biologically authentic CA dinucleotides (posi-
tions 27 and 29 using our nomenclature, Figure 6). These results imply that the stem-loop secondary
structure of RD nascent pre-mRNA is involved in enabling preferential cleavage at position 27. The
presence of the HDE sequence appears to be required to avoid non-specific cleavage, although
cleavage at position 27 was still observed when the HDE was removed (Figure 6F). The involvement
of the HDE element in determining selectivity is supported by in vitro studies utilizing HeLa nuclear
extracts indicating that the HDE is a major factor in defining the cleavage site of RD histone pre-
mRNA (Scharl and Steitz, 1994). The work with isolated MBLAC1 reveals that it has potential to cat-
alyse cleavage at CA sites other than at positions 27 and 29, although the biological relevance of
these other reactions needs to be validated. Future work can also focus on establishing the details
of the kinetics of MBLAC1 catalysis and the structural features that enable its selectivity, including
the nature of its interactions with the stem-loop and the HDE element at the 3’ end of RD histone
pre-mRNA.
Further detailed work is required to compressively define the factors responsible for targeting
MBLAC1 to the RD histone pre-mRNA cleavage site. The available results indicate that it is possible
that the observed in vitro sequence specificity of MBLAC1 may enable recognition of core histone
pre-mRNA substrates without the requirement for as many additional factors as is necessary in the
case of CPSF73 (or that MBLAC1 requires different factors) (Sullivan et al., 2009b).
Consistent with previous reports (Dominski et al., 2005; Kolev et al., 2008; Sullivan et al.,
2009a), we found that CPSF73 promotes RD histone pre-mRNA processing. However, it is likely that
CPSF73 is relatively more important than MBLAC1 in RD histone pre-mRNA processing outside of
S-phase, reflecting its essential role in the biosynthesis of polyadenylated mRNA, including that of
multiple histone variants (Marzluff et al., 2008; Marzluff et al., 2002; Wagner et al., 2007).
CPSF73 could well also be wholly or partly responsible for processing of defective RD histone pre-
mRNA that subsequently undergoes polyadenylation (Sullivan et al., 2009b) when MBLAC1 is
depleted in cells. Reported biochemical work with CPSF73 in its isolated form has only been carried-
out with few histone pre-mRNA model sequences (Kolev and Steitz, 2005). Thus, it is possible that
both CPSF73 and MBLAC1 selectively impact on the rates of maturation of different histone pre-
mRNA substrates in vivo, opening up the possibility for selective modulation of the biosynthesis of
RD histone variants. Although further validation work is required, our observations in cells support
Figure 6 continued
mutMBLAC1 (MUT). Cleavage products of the RNA 1 are compared with those of the differently modified fragments. Schematic views of the RNA
fragments are shown. The schematics show the numbering assigned to the possible cleavage sites present in each RNA; arrows indicate the
physiologically major (red) and minor (blue) cleavage sites. The CA dinucleotide corresponding to the major cleavage site is in red. Sequence or
structural modifications of each RNA are in yellow. The size of processed RNA products is indicated when appropriate. Unprocessed RNA fragments
corresponding to nucleotides 1 to 29 and 1 to 27 of the WT RNA 1 were used as mass markers and indicated as 29 and 27, respectively. Note that the
29 and 27 markers migrate more slowly on gel electrophoresis compared to the corresponding fragments generated by MBLAC1 catalysis in positions
27 and 29. This observation is explained by the presence of an extra negatively charged phosphate group on the 5’end of the products generated by
MBLAC1 catalysis, compared to the markers, as expected during maturation of histone transcripts (Furger et al., 1998).
DOI: https://doi.org/10.7554/eLife.39865.015
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also the proposal that MBLAC1 and CPSF73 impact to different extents on similar genes, possibly
compensating for depletion of one another in cells (Figure 4—figure supplement 2).
Our genetic and cellular studies imply that MBLAC1 inhibition may selectively slow down S-phase
progression in cancer cells. Thus, MBLAC1 may represent a new S-phase specific cancer target. The
true bacterial MBLs involved in antibacterial resistance have been shown to be amenable to small
molecule targeting (Pettinati et al., 2016), and it is likely that human MBL-fold endonucleases will
also be sensitive to small molecule inhibition. Our results suggest that targeting MBLAC1 may not
be as toxic as CPSF73, which has a pleiotropic role in polyadenylated pre-mRNA processing
(Mandel et al., 2006). Thus, the development of MBLAC1 inhibitors, likely for use in combination
with other drugs, is of interest from the cancer treatment perspective. Finally, it is notable that rela-
tively non-selective zinc ion chelating compounds, including HDAC inhibitors such as SAHA (subera-
nilohydroxamic acid) (West and Johnstone, 2014), are already used for cancer treatment via
S-phase targeting. It is possible that these, at least in part, work by inhibiting metal dependent
endoribonucleases, such as CPSF73 and MBLAC1.
Materials and methods
Reagents and antibodies
Unless otherwise specified, reagents were from Sigma-Aldrich. Antibodies used were: goat anti-
MBLAC1 (sc-243427), HRP-conjugated donkey anti-goat (sc-2020), goat anti-Lamin B1 (sc-30264),
mouse anti-Cyclin D (sc-20044), mouse anti-Cyclin E (sc-247) (all from Santa Cruz Biotechnology,
Inc.); rabbit anti-MBLAC1 (ARP70842_P050) (Aviva System Biology); mouse anti-His tag (ab18184),
rabbit anti-His tag (ab9108), mouse anti-Histone H3 (ab10799), HRP-conjugated mouse anti-b-actin
(ab49900) (all from Abcam); HRP-conjugated goat anti- rabbit (170–6515) (Biorad); rabbit anti-
CPSF73 (A301-091A) (Bethyl Laboratories, Inc,); mouse anti-Lamin A/C (4777) (Cell Signaling Tech-
nology); mouse anti-FLAG M2 (F3165) and mouse anti-a-tubulin (T5168) (Sigma-Aldrich); HRP-conju-
gated goat anti-mouse (W402B) (Promega Corporation); FITC mouse anti-BrdU (364104) (BioLegend
Inc.). Alexa fluor secondary antibodies used in immunofluorescence microscopy experiments were
from Molecular Probes (Thermo Fisher Scientific).
Recombinant MBLAC1 production in E. coli and purification
cDNA (codon optimised for expression in E. coli) encoding for MBLAC1 (GeneART, Thermo Fisher
Scientific) was inserted into the pCOLD I vector (Addgene) in order to produce MBLAC1 with an N-
terminal hexa-histidine tag (6xHis) with an N-terminal C human rhinovirus (HRV3C) protease cleavage
site. Recombinant MBLAC1 protein was produced in E. coli BL21 (DE3) cells grown in 2TY growth
media with 50 mg/mL ampicillin at 37˚C to mid-exponential phase (OD 600 = 0.6–0.8). MBLAC1 pro-
duction was induced by addition of isopropyl b-D-1-thiogalactopyranoside (IPTG) (0.5 mM) supple-
mented with 50 mM zinc sulfate while incubating at 15˚C. Cells were harvested by centrifugation
(6500 x g, 8 min) after 18 hr and frozen in liquid nitrogen. The cell pellet (~20 g) was added to 100
mL of lysis buffer (20 mM 4-(2-hydroxyethyl) 1-piperazineethanesulfonic acid (HEPES), pH 7.5, 500
mM sodium chloride, 5 mM imidazole), lysed by sonication followed by centrifugation (20,000 x g,
20 min). MBLAC1 was purified by loading the supernatant onto a 5 mL Ni-affinity column (GE Health-
care). The equilibration buffer was the same as the lysis buffer. The elution buffer additionally con-
tained 500 mM imidazole and was used to form an imidazole gradient (from 5 to 500 mM) to elute
the His-tagged protein. MBLAC1 was then loaded onto a S200 (300 mL) gel filtration column using
20 mM HEPES, pH 7.5, 500 mM sodium chloride as the running buffer. Fractions containing protein
were analysed by SDS-PAGE. The 6x-His tag was cleaved by addition of HRV3C protease (overnight
incubation at 4˚C), then purified by Ni-affinity chromatography to remove the cleaved tag. The resul-
tant purified MBLAC1 (~27 kDa) was buffer exchanged into 25 mM HEPES, pH 7.5, 30 mM sodium
chloride, then concentrated to 23 mg/mL using a Centricon concentrator (10 k MW cutoff) (Merck)
(at 3000 x g) until the desired volume was achieved.
Crystallization and structure determination
Crystallization was performed using the sitting drop vapor diffusion method using Art Robbins 96
well - three subwell Intelliplates and a protein:well drop size of 200 nL:100 nL,100 nL:100 nL, 100
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nL:200 nL for each subwell condition. MBLAC1 crystallised over ~24 hr using the following condi-
tions: JCSG-plus condition 94, 0.1 M bis Tris pH 5.5, 0.2 M ammonium acetate, 25 % w/v PEG 3350
(protein to reservoir ratio 2:1, 1:1, and 1:2) (Molecular Dimensions). Crystallization conditions were
optimised by varying the ammonium acetate concentration (0.14–0.25 M) and PEG 3350 percentage
(23–30%). The resultant crystals (~150300 mm) obtained in 0.1 M Bis Tris pH 5.5, 0.18 M ammonium
acetate, and 25 % w/v PEG 3350, were cryo-protected in well-solution diluted to 12.5% sucrose for
30 s, then harvested using nylon loops followed by cryo-cooling and storage under liquid nitrogen.
Data were collected on a single crystal at 100 K at the Diamond Light Source Synchrotron (beamline
I04, 1.28268 A˚ wavelength) to 1.8 A˚ resolution. Data were autoprocessed at the beamline using XDS
(Kabsch, 2010) and CCP4-SCALA (Evans, 2006) in XIA2 (Winter, 2010). The MBLAC1 structure was
solved by molecular replacement (MR) using the PHASER subroutine within PHENIX (Read, 2001;
Adams et al., 2004; Adams et al., 2010) with an ensemble structure as a search model based on 11
crystal structures identified by the Phyre two modelling server (Kelley et al., 2015) using the
MBLAC1 protein sequence as search input. Refinement was carried out by iterative rounds of model
building using Coot (Emsley et al., 2010) and maximum likelihood restrained refinement using PHE-
NIX (Afonine et al., 2005). Ramachandran statistics calculated 98.27% most favored geometry,
1.61% additionally allowed and 0.12% outliers. Data collection, processing, and structure refinement
statistics are given in Table 1 (related to Figure 1).
Non-denaturing electrospray ionization mass spectrometry
MBLAC1 purified from E. coli was diluted to 15 mM in 15 mM ammonium acetate buffer (pH 7.5).
The cone voltage for the acquisition of the spectra was 80 V. Electrospray ionization mass spectra of
the apo-enzyme were acquired in the positive ionization mode after overnight metal removal treat-
ment by addition of 20 mM ethylenediaminetetraacetic acid (EDTA) to the protein solution.
Inductively coupled plasma mass spectrometry (ICP-MS)
Wild-type MBLAC1 was produced in E. coli or HEK293 cells; 30 mg of the resultant purified protein
was then buffer exchanged into 20 mM HEPES pH 7.5, 50 mM NaCl buffer prepared using ‘ultra-
pure’ water. Concentrations of Zn, Fe, Mn, Ni, and Co divalent ions were measured in triplicate. ICP-
MS experiments and data analysis were carried out by the ICP-MS Trace Element Small Research
Facility of the Earth Sciences Department, Oxford University.
Cell culture and transfection
HeLa (ATCC) and HEK293 (kindly provided by Prof. Peter McHugh) cells were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine serum, and 2 mM L-glutamine, at
37˚C in a humidified incubator (5% CO2). To generate the construct MBLAC1 6xHis-pCDNA 3.1, an
appropriate sequence coding for MBLAC1 (GeneART, Thermo Fisher Scientific) was amplified by
PCR to introduce a C-terminal 6xHis tag, then cloned into the pCDNA 3.1 vector (Invitrogen). Both
HeLa and HEK293 cells were transiently transfected with the MBLAC1 6xHis-pCDNA3.1 construct
using the Fugene HD transfection reagent (Promega), following the manufacturer’s instructions.
MBLAC1 production was monitored by western blotting, 24 and 48 hr after transfection. To gener-
ate a stable cell line overexpressing MBLAC1, HEK293 cells were transfected with the MBLAC1
6xHis-pCDNA 3.1 construct using the Fugene HD transfection reagent (Promega), following the
manufacturer’s instructions. Stably transfected cells were selected by addition of geneticin (G418) (1
mg/ml) to the cell culture media; cell clones were generated by limiting dilution plating. Clones
were analysed by western blotting for their capacity to produce MBLAC1.
HEK293 expressed MBLAC1 production and purification
The best producing MBLAC1 HEK clone (c27) was adapted to serum-free growing conditions (Free
style medium, Invitrogen) and cultivated in spinning culture at 37˚C in a humidified incubator (8%
CO2) in the presence of 20 mM heparin sodium salt. Cell medium containing secreted 6xHis-tagged
MBLAC1 was harvested every 48 hr and stored at  20˚C until used. For purification, 10 mM imidaz-
ole was added to 1 L of clarified cell medium before loading onto a 1 mL Ni-affinity column (GE
Healthcare) equilibrated with 25 mM HEPES, pH 7.5, 500 mM sodium chloride, 10 mM imidazole.
The elution buffer additionally contained 500 mM imidazole and was used to form an imidazole
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gradient (from 10 to 500 mM) to elute the His-tagged protein. Fractions containing protein were
analysed by SDS-PAGE. The solution was concentrated to about 100 mL using a Centricon concentra-
tor (10 k MW cutoff) (Merck) (at 3000 x g) and exchanged into 25 mM HEPES pH 7.5, 50 mM NaCl
using 0.5 mL Micro BiospinTMsix desalting columns (Biorad). The obtained protein solution was con-
centrated to about 5 mg/mL and its purity determined by SDS PAGE. Alternatively, wild-type
HEK293 cells adapted to serum-free growing conditions (Free style medium, Invitrogen) were tran-
siently transfected with the MBLAC1 6xHis-pCDNA 3.1 encoding constructs (for the expression of
both wild-type and active site mutant MBLAC1) using the Expi293 expression system (Thermo Fisher
Scientific), following the manufacturer’s instructions. Interestingly, mutMBLAC1, unlike wtMBLAC1,
was not secreted into the cell medium. Therefore both wild-type and active site mutant MBLAC1
were purified as previously described following cell lysis by sonification.
Single point mutagenesis
Site-directed residue substitutions of MBLAC1 were performed using Pfu Turbo DNA polymerase
(Agilent Technologies) according to the manufacturer’s protocol. Primers used to generate the
mutants were designed following the manufacturer instructions and are listed in Table 2. The
pCOLD I vector (used to overexpress MBLAC1 in E. coli) was employed as template DNA. Plasmid
DNA with the correct mutation were used to transform E. coli BL21 (DE3) cells as described above.
MBLAC1 mutants expressed in E. coli were produced and purified similarly to wild-type enzyme, as
previously described.
Subcellular fractionation
Cytoplasmic and nuclear subcellular fractions were prepared as follows: HeLa cells were washed
twice with ice-cold PBS, then suspended in harvest buffer (10 mM HEPES KOH pH 7.9, 50 mM NaCl,
0.5 M sucrose, 0.5% Triton X-100, 1 mM DTT and protease inhibitor cocktail). After incubation for 5
min on ice, cells were centrifuged (100 x g, 10 min, 4˚C) to pellet nuclei. The supernatant (containing
cytosolic and membrane proteins) was centrifuged (14,000 x g, 10 min, 4˚C) and stored. The nuclear
pellet was resuspended and washed by centrifugation in buffer A (10 mM HEPES KOH pH 7.9, 10
mM KCl, 1 mM DTT and protease inhibitor cocktail) (100 x g10 min, 4˚C). The obtained nuclear pel-
let was resuspended in 4 volumes of buffer C (10 mM HEPES KOH pH 7.9, 200 mM NaCl, 0.1 % NP-
40, 1 mM DTT and protease inhibitor cocktail) and vortexed at 4˚C for 30 min. The nuclear lysate
was then centrifuged (15 min at 14,000 x g at 4˚C). Proteins concentrations of both cytoplasmic and
nuclear fractions were measured using the Bradford reagent. The subcellular fractions were then
evaluated by western blot analysis.
In vitro RNA degradation assays
DNA sequences coding for a portion of the human histone 2H3C (HIST2H3C) (350 nt), and the WT
and MUT shorter forms of the human histone 2H3C (HIST2H3C) (168 nt) genes with a 5’ T7 RNA
polymerase promoter sequence were used as templates to generate internally [32P] labeled RNA
substrates by in vitro transcription (MEGAscript T7 Kit, Thermo Fisher Scientific). The reaction was
carried out following the manufacturer’s instructions by adding an excess of [a-32P] UTP to the reac-
tion mixture. In vitro transcription products were fractionated on a 6% denaturing polyacrylamide/
urea gel. The generation of the radiolabeled RNA substrates was monitored by autoradiography.
The radiolabeled RNA was then gel purified and resuspended in 80 mL ddH2O. For the 5’ [g-
32P]
ATP labeled substrates listed in Table 1, RNA fragments were purchased from Integrated DNA
Technologies and 1 mg of each RNA was treated with T4 polynucleotide kinase (New England Biol-
abs) in the presence of an excess of [g-32P] ATP. The obtained 5’ [g-32P] ATP labeled substrates were
then gel purified using a 10% denaturing polyacrylamide/urea gel and resuspended in 60 mL ddH2O.
Cleavage assays were carried out in a mixture (10 ml) containing: 1 mL of labeled RNA substrates
(~600 ng of [a-32P] UTP substrate (~5 mM),~16 ng of [g-32P] ATP fragments (~1 mM)), 500 ng (~15 mM)
of recombinant wild-type or the active site variant MBLAC1 produced in both E. coli and HEK293
cells, or 50 ng (~1.5 mM) of recombinant wild-type or the active site variant produced in HEK293 cells
and 1x reaction buffer (20 mM HEPES KOH pH 7.5, 50 mM KCl, 10 mM MgCl2, 0.5 mM DTT, 0.05%
Triton X-100, 5% glycerol) at 37˚C. The reaction was stopped at the appropriate time point by phe-
nol-chloroform extraction and ethanol precipitation. RNA degradation products were then
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Table 2. Oligonucleotide primers and single guide RNA targeting sequences used in site directed
mutagenesis, RT-qPCR experiments and CRISPR/CAS9 mediated KD studies.
Abbreviations: GB, gene body; RT, read through. Note that the standard BBL numbering system has
been used (Galleni et al., 2001).
Oligonucleotide primers used for site directed mutagenesis
E. coli produced HSE
H196A_F GCAACACCGGGTGCTGGTGGTCAGCG
H196A_R CGCTGACCACCAGCACCCGGTGTTGC
D221A_F GTTGTTGCCGGTGCTGTTTTTGAACGTG
D221A_R CACGTTCAAAAACAGCACCGGCAACAAC
H263A_F GGTTGTTCCTGGTGCTGGTCCGCCTTTTCG
H263A_R CGAAAAGGCGGACCAGCACCAGGAACAACC
Oligonucleotide primers used in RT-qPCR experiments
GAPDH_GB_F (intron) ACCCAGAAGACTGTGGATGG
GAPDH_GB _R (intron) TTCAGCTCAGGGATGACCTT
GAPDH _RT_F TCCAGCCTAGGCAACAGAGT
GAPDH _RT_R TGTGCACTTTGGTGTCACTG
HIST1H2BC_GB_F ACCTCCAGGGAGATCCAGAC
HIST1H2BC_GB_R AGCTGGTGTACTTGGTGACG
HIST1H2BC_RT_F CTCCAGGGAGATCCAGACGG
HIST1H2BC_RT_R GCTCTTTTAGTGGGTATCTGGG
HIST4H4_GB_F GAAGGTGCTGCGGGACAATA
HIST4H4_GB_R AAGACTTTGAGGACTCCCCG
HIST4H4_RT_F CGCGCAACGCAGTAGTGACC
HIST4H4_RT_R CATTCAGCTTTCGGGCTTGCAGGTA
HIST2H2AC_GB_F GGCTCGGGACAACAAGAAGA
HIST2H2AC_GB_R AGAACGGCCTGGATGTTAGG
HIST2H2AC_RT_F GAAAGCCACAAAGCCAAAAGC
HIST2H2AC_RT_R GGCTTGACACCATACTCATTCACC
HIST1H3G_GB_F CTGAGCTGCTGATCCGCAAG
HIST1H3G_GB_R GGCGAGCGAGCTGAATGTCC
GAPDH_GB_F (exon-exon) AAGGTGAAGGTCGGAGTCAA
GAPDH_GB _R (exon-exon) AATGAAGGGGTCATTGATGG
r18S_F GGCCCTGTAATTGGAATGAGTC
r18S_R CCAAGATCCAACTACGAGCTT
CRISPR/Cas9 single guide RNA (sgRNA)
Location sgRNA targeting sequences
5’ targeting ACAGCGGCTCGGTCCGCATGAGG
3’ targeting TGCACTAATCAGCCTCGAGAGGG
CRISPR/Cas9 sequencing primers
Primers sequence
CRISPR/Cas9_F CAGAGAACCGAGGCTTAGGG
CRISPR/Cas9_R GAAGCTCCCACCCTTGACTG
CRISPR/Cas9 RT-qPCR primers
Primers sequence
HSE_set1_F ATCACATCGGGAACTTGGGG
HSE_set1_R CACCACGGTGCCCAGAG
Table 2 continued on next page
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fractionated on 6, 8 or 10% denaturing polyacrylamide/urea gel and the data were analysed by
Phospho-Imager (Fujifilm FLA 5000 imager).
siRNA transfection and cell synchronization
About 50% confluent HeLa cells were transfected with a SMARTpool of siRNA for MBLAC1 or
CPSF73 (GE Dharmacon), or with a negative control siRNA (Luciferase), using the Lipofectamine
RNAiMAX transfection reagent (Invitrogen) following the manufacturer’s instructions. Cells were
transfected with a final concentration of 10 nM siRNA and knockdown efficiency was assessed 48 hr
post transfection by western blot analysis. Transfected HeLa cells were synchronised using the dou-
ble thymidine block method (Harper, 2005). In brief, 6 hr post-siRNA transfection, cells were treated
with 2 mM thymidine (final concentration) for 18 hr; the thymidine was then removed for 9 hr, and
then was added again (2 mM) for 15 hr. Cells were then washed with PBS twice, and harvested at
different time points after release from the block; alternatively, cells were washed with PBS twice
and treated with 10 mM of 5-bromo-2’-deoxyuridine (BrdU), for 30 min or 1 hr. BrdU treated cells
were washed with PBS to remove the unincorporated BrdU and then harvested at different time
points for cell cycle analysis. Similarly, wt and CRISPR/cas9 mediated MBLAC1 kd HeLa cells were
synchronised and BrdU treated as described above.
Cell cycle analysis
Synchronised HeLa cells were washed with PBS buffer and fixed in ice-cold ethanol overnight. DNA
was stained with a propidium iodide (PI) solution containing 0.1% Triton X-100 in PBS, 0.2 mg/ml
RNase A, 0.02 mg/ml PI for 30 min at room temperature. Alternatively, BrdU-treated cells were fixed
by adding ice-cold 70% ethanol overnight. Cells were then incubated with 2 N HCl, 0.5% Triton
X-100 for 30 min at room temperature and washed with 0.1 M sodium tetraborate buffer, pH 8 for 2
min. Cells were washed and incubated with a FITC conjugated anti-BrdU antibody (BioLegend) for 1
hr at room temperature. PI staining followed as described above. Cell cycle profiles were analysed
by flow cytometry with FACSCalibur (BD Biosciences) and processed using FlowJo software (Tree
Star).
Chromatin RNA extraction and libraries preparation
Chromatin RNA (ChrRNA) was extracted from HeLa cells 48 hr after siRNA transfection to coincide
with the end of the second thymidine block time-point. Approximately 3  106 cells were resus-
pended in 500 mL of ice-cold RLB buffer (10 mM Tris-HCl, pH 7.5, 140 mM NaCl, 0.5% nonidet-P40
(NP-40), 1.5 mM MgCl2) and lysed by adding an equal volume of RLB buffer with 24% (m/v) sucrose.
Nuclei were collected by centrifugation (14,000 x g) at 4˚C for 10 min. Isolated nuclei were resus-
pended in 120 ml of NUN1 buffer (20 mM Tris-HCl, pH 7.9, 75 mM NaCl, 0.5 mM EDTA, 50% Glyc-
erol, 0.125 mM PMSF, 1 mM DTT), followed by addition of 1.2 ml NUN2 buffer (20 mM HEPES KOH
pH 7.6, 7.5 mM MgCl2, 0.2 mM EDTA, 300 mM NaCl, 1 M urea, 1 % NP-40, 1 mM DTT). Nuclei
were incubated for 15 min on ice with mixing by vortexing for 5 s every 5 min. Chromatin pellets
were precipitated by centrifugation (14,000 x g) at 4˚C for 10 min and then resuspended in 200 ml
HSB buffer (10 mM Tris-HCl, pH 7.5, 500 mM NaCl, 10 mM MgCl2) in presence of 4 U TURBO DNase
(Ambion) and incubated at 37˚C for 20 min. Following a 20-min proteinase K treatment (Roche) at
37˚C, chromatin RNA (chrRNA) was phenol-chloroform extracted and ethanol precipitated. RNA was
resuspended in 200 mL of 1x TURBO DNAse buffer in presence of 4 U TURBO DNase and incubated
at 37˚C for 30 min. The entire procedure of extraction, precipitation and DNase treatment was
Table 2 continued
Oligonucleotide primers used for site directed mutagenesis
E. coli produced HSE
HSE_set2_F GCTCTGGGCACCGTGG
HSE_set2_R GCGAGGCTTCCCTTAACACT
DOI: https://doi.org/10.7554/eLife.39865.016
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repeated twice. RNA was then extracted and precipitated again, prior to solubilisation in 75 mL of
RNase free water.
Prior to RNA libraries preparation, rRNA was depleted using the Ribo-Zero Magnetic kit (Illumina)
from 2.5 mg of ChrRNA. Libraries were prepared starting from 100 ng chrRNA using the NEBNext
Ultra Directional RNA Library Prep kit for Illumina (NEB) following the manufacturer’s instructions.
Deep sequencing using Hiseq4000 with paired-end (75 bp) runs was performed by the Wellcome
Trust Centre for Human Genetics (WTCHG), Oxford, UK.
Real time PCR analyses
ChrRNA was extracted from synchronised HeLa cells 48 hr after siRNA transfection as described
above. For reverse transcription, 500 to 900 ng of ChrRNA from each sample was used to generate
single-strand cDNA by incubation with random hexamers (Qiagen) and Superscript III reverse tran-
scriptase (Life Technologies). Quantitative RT-PCR was performed using the SYBR Green Master Mix
(Qiagen). Relative RNA levels were calculated using the DCt method. Data were acquired and ana-
lysed using Rotor-GeneQ (Qiagen). Defects in 3’ end transcription termination were evaluated using
amplicons located downstream of the 3’ untranslated region (3’ UTR) of RD histone genes. The rela-
tive abundance of unprocessed sequences was normalised to the relative abundance of an amplicon
covering a portion of the GAPDH gene body (GB) or to the corresponding histone GB abundance.
Primers used are listed in Table 2. Similarly, chrRNA was extracted from synchronised wild-type and
CRISPR/Cas9-mediated MBLAC1-depleted HeLa cells; cDNA libraries and quantitative RT-PCR were
performed as above.
Chromatin RNA-Seq data processing
GRCh38 was used as a reference genome. RNA-sequencing reads were trimmed using Cutadapt
1.8.3 (Martin, 2011). An in-house Perl scripts Perl script was used to remove the reads left unpaired.
The remaining reads were then aligned to the human reference genome with Tophat 2.0.13
(Sullivan et al., 2009b; Sun et al., 2006) using parameters: tophat -g 1 r 3000 –no-coverage-search.
Aligned reads were processed to only include properly paired, properly mapped reads with no more
than two mismatches using SAMtools 1.2 (Li et al., 2009). Data were scaled to library size (genome-
CoverageBed) using Bedtools (Quinlan and Hall, 2010). For data vizualization, trackhubs for the
UCSC browser were created by employing the UCSC bedGraphToBigWig tool (Kent et al., 2002).
For the gene body normalised plots, expression levels (as reads per kilobase per million mapped
reads, RPKMs) were calculated for a region of ’TES-100bp’ for each gene in all the three samples,
namely, LUC, MBLAC1 and CPSF73. These values were then used to normalise each base position
followed by plotting them using Python script. Gene body normalised plots were then log two
transformed.
RNA-chromatin immunoprecipitation analysis
Wild-type and MBLAC1 C-terminal FLAG knock in HeLa cells were synchronised in early S-phase
using a double thymidine block and used in RNA-chromatin immunoprecipitation (RNA-ChIP) experi-
ments as described by B. K. Sun and J. T. Lee (Sun et al., 2006). An additional TURBO DNase
(Ambion) treatment was repeated at the end of the procedure to ensure complete chromatin diges-
tion. The obtained immunoprecipitated RNA was used to prepare cDNA libraries and quantitative
RT-PCR was performed as above. RNA levels were calculated using the standard curve method.
Data were acquired and analysed using Rotor-GeneQ (Qiagen). Primer sets used in the experiments
are listed in Table 2.
CRISPR/Cas9-mediated MBLAC1 deletion
Single guide RNA (sgRNA) constructs aiming to delete the MBLAC1 gene in HeLa cells were
designed and produced by the Genome Engineering Oxford Facility, Oxford University, UK (Table 2).
HeLa cells were transiently co-transfected with two sgRNA constructs (vector epX459(1.1)), both car-
rying the engineered hSpCas9(1.1) gene (Slaymaker et al., 2016) and a sgRNA cassette targeting
the 5’ or 3’ region flanking the MBLAC1 gene using Fugene HD transfection reagent (Promega), fol-
lowing the manufacturer’s instructions. 24 hr after transfection, cells were exposed to puromycin (2
mg/ml) for 24 hr to positively select transfected cells. After recovery, cells were harvested and used
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to select MBLAC1-depleted cell clones by limiting dilution plating and to isolate genomic DNA to
evaluate the gene deletion efficiency by PCR (Table 2). Genomic DNA was then extracted from cell
clones and PCR reactions amplifying the DNA region flanking the sgRNA targeting sites were per-
formed to confirm MBLAC1 gene deletion. PCR products corresponding to the wt gene or to the
gene deletion were gel purified and their sequence confirmed by Sanger sequencing. Total RNA
was then extracted from cell clones carrying the MBLAC1 deletion using TRI reagent (Ambion) fol-
lowing the manufacturer’s instructions. RT-qPCR analyses were performed to evaluate MBLAC1
mRNA levels after CRISPR/Cas9-mediated depletion as above. RT-qPCR products were analysed by
Sanger sequencing.
CRISPR/Cas9-mediated MBLAC1 C-terminal FLAG knock in generation
HeLa cells were transiently co-transfected with a single guide RNA (sgRNA) construct targeting the
3’ region flanking the MBLAC1 gene (previously used to delete the MBLAC1 gene in HeLa cells) and
with a pUC19 vector (NEB) carrying a FLAG tag sequence flanked at both 5’ and 3’ by ~300 nucleoti-
des sequence corresponding to the genomic sequence flanking the 3’ region of the MBLAC1 gene
using Fugene HD transfection reagent (Promega), following the manufacturer’s instructions. Similarly
to the CRISPR/Cas9-mediated MBLAC1 deletion, 24 hr after transfection, cells were exposed to
puromycin (2 mg/ml) for 24 hr to positively select transfected cells. After recovery, cells were har-
vested and used to select MBLAC1 knock in (Kin) cell clones by limiting dilution plating and to iso-
late genomic DNA to evaluate the FLAG sequence insertion efficiency by PCR (Table 2). Positive
cells clones were growth as usual and analysed by western blot to validate the FLAG tag insertion at
protein level using an anti-FLAG antibody.
Polyadenylated RNA selection
Total RNA was extracted from wild-type and CRISPR/Cas9-mediated MBLAC1-depleted HeLa cells
after synchronization in early S-phase using the TRI reagent (Ambion). The Dynabeads mRNA purifi-
cation kit (Ambion) was used to positively select polyadenylated RNA following the manufacturer’s
instructions; unbound RNA was considered as the unpolyadenylated RNA fraction. Both RNA frac-
tions were phenol-chloroform extracted and ethanol precipitated, then solubilized in 20 mL ddH2O.
For reverse transcription, 1 mg of total, polyadenylated and unpolyadenylated RNA from each sam-
ple was used to generate single-strand cDNA by incubation with random hexamers (Qiagen) and
Superscript III reverse transcriptase (Life Technologies). Quantitative RT-PCR was performed using
the SYBR Green Master Mix (Qiagen). RNA levels were calculated using the standard curve method.
Data were acquired and analysed using Rotor-GeneQ (Qiagen). Primer sets used in the experiments
are listed in Table 2).
Data analysis and statistics
The number of biological repeats and statistical tests (conducted in Microsoft Excel or GraphPad)
are indicated in the corresponding figure legends. Error bars representing s.e.m. are shown where
appropriate.
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